(Q28373127)

English

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

scientific article

In more languages

Statements

scholarly article

0 references

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease (English)

0 references

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

B Henry

1

0 references

S H Fox

2

0 references

D Peggs

3

0 references

A R Crossman

4

0 references

J M Brotchie

5

0 references

language of work or name

0 references

publication date

September 1999

0 references

Movement Disorders

0 references

14

0 references

5

0 references

744-53

0 references

Levodopa-induced dyskinesia: review, observations, and speculations

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Problems with current pharmacologic treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Bromocriptine and levodopa (with or without carbidopa) in parkinsonism

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Long-term treatment of parkinsonism with bromocriptine

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Anxiolytic-like effects of yohimbine in the murine plus-maze: strain independence and evidence against alpha 2-adrenoceptor mediation.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197).

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Functional evidence for a 5‐HT2B receptor mediating contraction of longitudinal muscle in human small intestine

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Pharmacological characterisation of [35S]-GTPgammaS binding to Chinese hamster ovary cell membranes stably expressing cloned human 5-HT1D receptor subtypes

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Comparison of the ?-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

3Hrauwolscine (α-yohimbine): A specific antagonist radioligand for brain α2-adrenergic receptors

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Core assessment program for intracerebral transplantations (CAPIT)

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Neuropharmacological studies in rodents on the action of RX 781094, a new selective α2-adrenoceptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Effects of an alpha2 antagonist ina 20-year-old Java monkey with MPTP-induced parkinsonian signs

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C744%3A%3AAID-MDS1006%3E3.0.CO%3B2-7

21 January 2018

Identifiers

10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28373127&oldid=1956544455"